Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is pleased to announce that it has recently engaged Richard A. Bender MD, FACP, a veteran multiple myeloma ("MM") clinician, key opinion leader and medical diagnostics expert to establish and chair TELO's MM clinical advisory board (the "Advisory Board").

Driven by the progress of TELO's clinical studies announced on September 14, 2022, and as part of the Company's commercialization strategy, the Company has prioritized the formation of an internationally recognized clinical advisory board to help guide the development and commercial launch of its predictive and prognostic tests for MM. In addition to clinical product development, the Advisory Board will provide direction with respect to regulatory pathways, product launch and marketing initiatives.

Dr. Bender is a board-certified oncologist who brings more than 40 years of experience in hematological malignancy with a special focus on MM. He received his medical degree from the UCLA School of Medicine and completed his internship and residency at UCLA-Harbor General Hospital followed by a hematology/oncology fellowship at the National Cancer Institute. His past titles include Medical Director for Hematology/Oncology for Quest Diagnostics, Medical Director for Hematology/Oncology for Kaiser Permanente in San Diego, and Chief Medical Officer for both Agendia and Signal Genetics. Dr. Bender has also served on the executive board of the San Diego Hospice and American Cancer Society and has been retained by the FDA as a member of the Hematology and Pathology Devices Advisory Committee. He continues to teach at the UCLA School of Medicine and has authored more than 80 peer-reviewed scientific articles and book chapters.

"I am very pleased to join the Telo Genomics' team and look forward to leading the Company's MM clinical advisory board," said Dr. Bender. "The promising TeloView technology is strongly supported by scientific and clinical evidence and addresses vital unmet clinical needs in the management of multiple myeloma, particularly for high-risk 'smoldering myeloma' patients."

TELO has recently completed the clinical validation of two prognostic tests that have been developed to address important unmet clinical needs in the management of MM. TELO's lead product is designed to identify high-risk smoldering multiple myeloma ("SMM") patients who are likely to benefit from earlier treatment intervention. Of greater importance, the test will also identify the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment, but who can be regularly monitored using TELO's test. The Company's second MM assay is designed to identify newly diagnosed MM patients who are most likely to develop treatment resistance and relapse. Identifying these patients will permit treating physicians to modify their chemotherapy regimens in a timely manner. The test facilitates regular monitoring and, consequently, enables real time treatment modification, as indicated.

About Multiple Myeloma

Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. Although the introduction of new generation therapy, including targeted immunotherapy, has increased the median survival rate to over 5 years, MM is still considered incurable. Two asymptomatic precursors, MGUS and SMM generally precede the progression to classic, symptomatic MM at yearly rates of 1% from MGUS and at 15% from SMM, respectively. To date, identifying patients who will more rapidly progress to MM remains an important unmet clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important and unmet need. Notably, the total addressable market for both of these MM assays is over 750,000 tests per year in the US.

About TELO

Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, TELO is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, TELO-MM is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. For more information please visit www.telodx.com.

For further information, please contact:

Hugh Rogers,
Director
416-673-8487
This email address is being protected from spambots. You need JavaScript enabled to view it.
MaRS Centre, South Tower,
101 College Street, Suite 200,
Toronto, ON, M5G 1L7
www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView^® platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.